INBX Key Statistics, Chart & Performance
The current stock price of INBX is 72.86 USD. In the past month the price decreased by -13.79%. In the past year, price increased by 412.74%.
INBX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About INBX
Company Profile
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. The company is headquartered in La Jolla, California and currently employs 156 full-time employees. The company went IPO on 2024-05-28. The firm utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
Company Info
INHIBRX BIOSCIENCES INC
11025 N. Torrey Pines Road, Suite 140
La Jolla CALIFORNIA 92037 US
CEO: Mark P. Lappe
Employees: 156
Phone: 18587954220
INHIBRX BIOSCIENCES INC / INBX FAQ
What does INBX do?
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. The company is headquartered in La Jolla, California and currently employs 156 full-time employees. The company went IPO on 2024-05-28. The firm utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
What is the current price of INBX stock?
The current stock price of INBX is 72.86 USD. The price decreased by -3.11% in the last trading session.
Does INBX stock pay dividends?
INBX does not pay a dividend.
What is the ChartMill technical and fundamental rating of INBX stock?
INBX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is INHIBRX BIOSCIENCES INC (INBX) stock traded?
INBX stock is listed on the Nasdaq exchange.
Is INHIBRX BIOSCIENCES INC (INBX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INBX.
INBX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to INBX. When comparing the yearly performance of all stocks, INBX is one of the better performing stocks in the market, outperforming 99.4% of all stocks.
INBX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INBX. While INBX seems to be doing ok healthwise, there are quite some concerns on its profitability.
INBX Financial Highlights
Over the last trailing twelve months INBX reported a non-GAAP Earnings per Share(EPS) of -10.02. The EPS decreased by -108.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 843786% | ||
| ROA | 950.9% | ||
| ROE | 4582.06% | ||
| Debt/Equity | 2.71 |
INBX Forecast & Estimates
6 analysts have analysed INBX and the average price target is 12.24 USD. This implies a price decrease of -83.2% is expected in the next year compared to the current price of 72.86.
For the next year, analysts expect an EPS growth of -107.78% and a revenue growth 1200% for INBX